Core Viewpoint - Shanghai Pharmaceuticals Group Co., Ltd. is set to hold an annual performance briefing for 2025 on April 8, 2026, to discuss its operational results and financial status with investors [2][3]. Group 1: Annual Performance Briefing - The annual performance briefing will take place on April 8, 2026, from 10:00 to 11:00 AM at the Shanghai Stock Exchange Roadshow Center [2][5]. - Investors can submit questions for the briefing from March 31, 2026, to April 7, 2026, before 4:00 PM [2][6]. - The company aims to provide a comprehensive understanding of its 2025 annual report, which will be released after the market closes on March 30, 2026 [2][3]. Group 2: Product Approval Announcement - Shanghai Pharmaceuticals' subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the production of Dihydroxypropyl Theophylline Injection [8][9]. - The drug is classified as a Class 3 chemical drug and is indicated for conditions such as bronchial asthma and obstructive pulmonary emphysema [9][11]. - The company has invested approximately RMB 3.14 million in the research and development of this drug, which is expected to enhance its market competitiveness [11].

Core Viewpoint - Shanghai Pharmaceuticals has received final approval from the U.S. FDA for its abbreviated new drug application (ANDA) for Oxcarbazepine Tablets, marking a significant milestone for the company in the U.S. market [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has successfully obtained final approval for the ANDA of Oxcarbazepine Tablets [1] - The drug is indicated for the treatment of partial seizures in patients aged 4 years and older, originally developed by Bial-Portela, Eisai, and Dainippon Sumitomo [1] - The ANDA application was submitted to the U.S. FDA in January 2018, with temporary approval granted in June 2020 for four specifications, leading to the recent final approval [1] - The company has invested approximately RMB 15.9371 million in research and development for this drug [1]